108384
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
经动脉化疗栓塞联合肝动脉灌注化疗与单纯经动脉化疗栓塞作为不可切除巨大肝细胞癌（＞10 厘米）初始局部治疗的对比：一项倾向评分匹配研究
Authors Liu C , Li J, Zhao M, Zheng L, Xiao JC
Received 18 May 2025
Accepted for publication 9 September 2025
Published 15 September 2025 Volume 2025:12 Pages 2083—2093
DOI https://doi.org/10.2147/JHC.S537950
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Professor Manal Hassan
Chong Liu,1 Jing Li,1 Ming Zhao,2 Lin Zheng,1,* Jin-Cheng Xiao1,*
1Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, People’s Republic of China; 2Department of Minimally Invasive Interventional Radiology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Cancer for Cancer Medicine, Guangzhou, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jin-Cheng Xiao; Lin Zheng, Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, 127 Dongming Road, Zhengzhou, 450008, People’s Republic of China, Tel +86-13838046795; +86-15838162655, Email 1377239957@qq.com; hyzhenglin@163.com
Purpose: Hepatocellular carcinoma (HCC) remains challenges in treatment, particularly when tumors are unresectable and huge. This study aimed to assess the safety and efficacy of combining transarterial chemoembolization (TACE) with hepatic arterial infusion chemotherapy (HAIC) for this patient population.
Patients and Methods: A retrospective review was conducted on patients with unresectable huge HCC (> 10 cm) who received either TACE-HAIC or TACE as initial regional treatment from January 2020 to December 2023. Tumor response, progression-free survival (PFS), overall survival (OS), and adverse events were evaluated by propensity score matching (PSM).
Results: Among the 242 patients included, 132 received TACE-HAIC and 110 received TACE. After PSM, 77 matched pairs were analyzed. The TACE-HAIC group had significantly higher objective response (74.0% vs 58.4%, P = 0.040) and disease control rates (93.5% vs 72.7%, P = 0.001) than the TACE group. TACE-HAIC therapy also led to longer PFS (median: 12.3 vs 7.4 months, P < 0.001) and prolonged OS (median: 26.8 vs 20.4 months, P = 0.006). Stratified analysis showed that patients in Barcelona Clinical Liver Cancer stage C had longer survival benefits in the TACE-HAIC group (median PFS: 10.5 vs 5.6 months, P < 0.001; median OS: 24.5 vs 19.8 months, P = 0.013). Among grade 3/4 adverse events, liver abscesses (P = 0.018) were more common in the TACE group.
Conclusion: Compared to TACE alone, TACE-HAIC therapy presented an acceptable safety profile, and offered improved local efficacy and prolonged survival benefits in patients with unresectable huge HCC (> 10 cm).
Keywords: liver cancer, chemoembolization, huge HCC, combination therapy
1Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, People’s Republic of China; 2Department of Minimally Invasive Interventional Radiology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Cancer for Cancer Medicine, Guangzhou, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jin-Cheng Xiao; Lin Zheng, Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, 127 Dongming Road, Zhengzhou, 450008, People’s Republic of China, Tel +86-13838046795; +86-15838162655, Email 1377239957@qq.com; hyzhenglin@163.com
Purpose: Hepatocellular carcinoma (HCC) remains challenges in treatment, particularly when tumors are unresectable and huge. This study aimed to assess the safety and efficacy of combining transarterial chemoembolization (TACE) with hepatic arterial infusion chemotherapy (HAIC) for this patient population.
Patients and Methods: A retrospective review was conducted on patients with unresectable huge HCC (> 10 cm) who received either TACE-HAIC or TACE as initial regional treatment from January 2020 to December 2023. Tumor response, progression-free survival (PFS), overall survival (OS), and adverse events were evaluated by propensity score matching (PSM).
Results: Among the 242 patients included, 132 received TACE-HAIC and 110 received TACE. After PSM, 77 matched pairs were analyzed. The TACE-HAIC group had significantly higher objective response (74.0% vs 58.4%, P = 0.040) and disease control rates (93.5% vs 72.7%, P = 0.001) than the TACE group. TACE-HAIC therapy also led to longer PFS (median: 12.3 vs 7.4 months, P < 0.001) and prolonged OS (median: 26.8 vs 20.4 months, P = 0.006). Stratified analysis showed that patients in Barcelona Clinical Liver Cancer stage C had longer survival benefits in the TACE-HAIC group (median PFS: 10.5 vs 5.6 months, P < 0.001; median OS: 24.5 vs 19.8 months, P = 0.013). Among grade 3/4 adverse events, liver abscesses (P = 0.018) were more common in the TACE group.
Conclusion: Compared to TACE alone, TACE-HAIC therapy presented an acceptable safety profile, and offered improved local efficacy and prolonged survival benefits in patients with unresectable huge HCC (> 10 cm).
Keywords: liver cancer, chemoembolization, huge HCC, combination therapy